We have active partnerships with top-tier academic medical centers, the top 15 oncology biopharma companies, the FDA, and the NCI, all focused on using data to accelerate the research and treatment of cancer. Our technology-first approach has allowed us to build RWE data sets with higher quality, accuracy, recency, and scale than any other cancer data that are available. We believe that existing clinical research paradigms are ill-equipped to answer the research questions that face drug developers, academic researchers, and regulators in the oncology space today.įlatiron Research is focused on innovating in the real-world evidence (RWE) and clinical trials space. Our platform enables cancer researchers and care providers to learn from the experience of every patient. I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care.
Medical writer salary research oncology at flatiron health registration#
I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Institutional Review Board approval of the study protocol was obtained prior to study conduct, and included a waiver of informed consent by WCG IRB. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. and Foundation Medicine Inc., which are independent subsidiaries of the Roche group. This study was sponsored by Flatiron Health, Inc. SS reports former employment at FMI as well as stock ownership in Pfizer, Roche and EQRx. MM also holds shares in Roche, GRAIL, and Illumina.
MM reports former employment at Flatiron Health and current employment at GRAIL, Inc. VF and LC report employment at Foundation Medicine, Inc., which is an independent subsidiary of the Roche Group, and stock ownership in Roche.
TS and JS also report equity ownership in Flatiron Health, Inc. TS, JS, and CCP report employment at Flatiron Health, Inc., which is an independent subsidiary of the Roche Group, as well as stock ownership in Roche. Ongoing monitoring and evaluation of the representativeness of these databases will be critical to help researchers and regulators contextualize evidence from the CGDBs, particularly as the CGDBs are expected to change over time due to increased adoption of CGP as part of routine clinical practice for a growing number of cancers. Observed variances could be due to several factors, including differences in CGP testing dynamics and data collection approaches used to create each of the databases. Conclusion This comparative analysis of real-world, US-based oncology databases provides crucial insights into the similarities and differences in patient characteristics across these three types of data sources.
0 kommentar(er)
